Seres Therapeutics (MCRB) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 9, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 8, 2026.

Voting matters and shareholder proposals

• Election of three directors: Stephen A. Berenson, Claire M. Fraser, Ph.D., and Richard N. Kender.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of amendment and restatement of the 2025 Incentive Award Plan to increase shares available.

• Approval to adjourn the meeting if more time is needed to solicit votes for Proposal 4.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and director nominees.